Goodbye Columbs ! New NRDOs Forego Discovery  

Oleh:

Thiel, Karl A.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 22 no. 9 (Sep. 2004), page 1087-1092.
Topik: discovery; NRDOs forego discovery

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.1 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Companies that eschew drug discovery in favor of in licensing have captured a lotof attention and investment over the past few years. But are these young companies really chasing a sustainable business model ? The only two sure things in life, the saying goes, are death and taxes. Have pity then for the poor biotech startup, which can't even count on the latter. Most discovery based companies have never earned taxable profits and many never will. The face long odds and daunting costs in creating new drugs, sometimes spending tens or even hundreds of millions of dollars just to see a product fail in a late stage clinical trial..

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali